Translating research into practice: the role of provider based research networks in the diffusion of an evidence-based colon cancer treatment innovation

Details

• Alternative Title:
  Med Care
• Personal Author:
  Carpenter, William R. ; Meyer, Anne-Marie ; Wu, Yang ; Qaqish, Bahjat ; Sanoff, Hanna K. ; Goldberg, Richard M. ; Weiner, Bryan J.
• Description:
  Background ; Provider-based research networks (PBRNs) – collaborative research partnerships between academic centers and community-based practitioners – are a promising model for accelerating the translation of research into practice; however, empirical evidence of accelerated translation is limited. Oxaliplatin in adjuvant combination chemotherapy is an innovation with clinical trial-proven survival benefit compared to prior therapies. The goal of this study is to examine the diffusion of oxaliplatin into community practice, and whether affiliation with the National Cancer Institute’s (NCI’s) Community Clinical Oncology Program (CCOP) – a nationwide cancer-focused PBRN – is associated with accelerated innovation adoption. ; Design, Setting, and Participants ; This retrospective observational study used linked SEER-Medicare and NCI-CCOP data to examine Medicare participants with stage III colon cancer initiating treatment in 2003 through 2006, the years surrounding oxaliplatin’s FDA approval. A fixed-effects analysis examined chemotherapy use among patients treated outside academic centers at CCOP-affiliated practices compared to non-CCOP practices. Two-group modeling controlled for multiple levels of clustering, year of chemotherapy initiation, tumor characteristics, patient age, race, comorbidity, Medicaid dual-eligibility status, and education. ; Results ; Of 4,055 community patients, 35% received 5-FU, 20% received oxaliplatin, 7% received another chemotherapy, and 38% received no chemotherapy. 25% of CCOP patients received oxaliplatin, compared to 19% of non-CCOP patients. In multivariable analysis, CCOP exposure was associated with higher odds of receiving guideline-concordant treatment in general, and oxaliplatin specifically. ; Conclusions ; These findings contribute to a growing set of evidence linking PBRNs with a greater probability of receiving treatment innovations and high quality cancer care, with implications for clinical and research policy.
• Subjects:
  • Adenocarcinoma
  • Antineoplastic Agents
  • Biomedical Research
  • Chemoradiotherapy, Adjuvant
  • Colonic Neoplasms
  • Diffusion of Innovation
  • Fluorouracil
  • Humans
  • Medicare
  • Organoplatinum Compounds
  More +
• Keywords:
  • colon cancer
  • translational research
  • diffusion of innovation
  • organization and administration
  • provider-based research networks
  • Chlorination
  • Household water treatment
  • Safe water storage
• Source:
  Med Care. 50(8):737-748
• Pubmed ID:
  22437624
• Pubmed Central ID:
  PMC3389231
• Document Type:
  Journal Article
• Funding:
  U55/CCR921930-02/PHS HHSUnited States/ ; N02 PC015105/PC/NCI NIH HHSUnited States/ ; 5R01CA124402/CA/NCI NIH HHSUnited States/ ; HHSN261200800726P/CO/NCI NIH HHSUnited States/ ; R01 CA124402-01A1/CA/NCI NIH HHSUnited States/ ; R01 CA124402/CA/NCI NIH HHSUnited States/ ; N01PC35136/CA/NCI NIH HHSUnited States/ ; N01PC35139/CA/NCI NIH HHSUnited States/ ; N01-PC-35136/PC/NCI NIH HHSUnited States/ ; N01-PC-35139/PC/NCI NIH HHSUnited States/ ; HHSN261200800726P/CD/ODCDC CDC HHSUnited States/
  More +
• Volume:
  50
• Issue:
  8
• Download URL:
  https://stacks.cdc.gov/view/cdc/110929/cdc_110929_DS1.pdf
• File Type:
  [PDF - 446.29 KB]
• Collection(s):
  CDC Public Access
• Main Document Checksum:
  urn:sha256:116e749d40d22ddde039b1740ae930e035b8bb9b2f39e8a3a5e635c6d6051f72